Through its Venture Capital unit, Evonik has invested in the start-up NUMAFERM and now holds a minority share in the biotechnology company, which is located in Düsseldorf. The investment was made as part of a seed financing round and also includes investments by High-Tech Gründerfonds, the Business Angels and Qiagen co-founders Detlev Riesner and Jürgen Schumacher, as well as the European Investment Fund. The volume of the overall round of financing is in the one-digit million-euro range. “Peptides and their applications are highly interesting for our growth engines Health & Care and Specialty Additives. In addition, Evonik has great competency in biotechnology. That makes NUMAFERM an outstanding strategic match for us,” says Bernhard Mohr, head of Venture Capital at Evonik.
Click here to read the full press release.